Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 3,477 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| PaxMedica Inc | PXMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0071 | -1.03% | 0.6849 | 08:11:27 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.692 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 21 | 3,477 | - | 0.372 - 29.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:11:26 | 72 | $ 0.6801 | USD |
PaxMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.11M | 7.41M | - | 0 | -18.29M | -2.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
PaxMedica News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PXMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7439 | 0.85 | 0.677 | 0.7417649 | 565,646 | -0.059 | -7.93% |
| 1 Month | 0.511 | 1.189 | 0.4011 | 0.7995219 | 7,245,702 | 0.1739 | 34.03% |
| 3 Months | 0.53 | 1.189 | 0.372 | 0.7830821 | 2,582,252 | 0.1549 | 29.23% |
| 6 Months | 3.3167 | 10.26 | 0.372 | 2.05 | 2,986,610 | -2.63 | -79.35% |
| 1 Year | 25.84 | 29.75 | 0.372 | 3.86 | 1,816,836 | -25.16 | -97.35% |
| 3 Years | 110.50 | 178.16 | 0.372 | 26.64 | 1,858,253 | -109.82 | -99.38% |
| 5 Years | 110.50 | 178.16 | 0.372 | 26.64 | 1,858,253 | -109.82 | -99.38% |
PaxMedica Description
| PaxMedica Inc an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). It focuses on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. It is also focused on the treatment of Human African Trypanosomiasis (or HAT). Its candidate PAX-102, proprietary intranasal formulation of suramin, as well as other new chemical entities that are more targeted and highly selective antagonists of particular purinergic receptor subtypes. |
